News Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Real-time Estimate Cboe BZX Other stock markets 01:06:25 2024-04-16 pm EDT			5-day change	1st Jan Change
16.03 ^USD	-0.74%		-4.93%	+69.93%

Feb. 09	Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	MT
Feb. 07	Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference	Mar. 06	BU
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	Feb. 09	MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M	Feb. 07	MT
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot	Feb. 07	AQ
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET	Feb. 07	BU
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	BU
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023	Jan. 31	BU
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	BU
Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	BU
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024	Dec. 26	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Nov. 24	MT
Sector Update: Health Care	Nov. 24	MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf	Nov. 24	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating	Nov. 22	MT
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference	Nov. 22	BU
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating	Nov. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Summary

Filters